parietaria judaica pollen extract

**Parietaria judaica pollen extract** is a standardized allergen extract derived from *Parietaria judaica* pollen and used as allergen-specific immunotherapy for **Parietaria-induced respiratory allergy**, especially allergic rhinitis, rhinoconjunctivitis, and mild allergic asthma in sensitized patients. It is administered as either **subcutaneous immunotherapy** or **sublingual immunotherapy** in the cited clinical literature. Its therapeutic mechanism is immune tolerance induction: repeated exposure to the causative pollen allergens is intended to desensitize patients, reduce clinical reactivity during pollen season, and modulate allergen-specific immune responses, including changes in immunoglobulin profiles and skin-test reactivity. Publicly cited development includes a multicenter open trial sponsored by **ROXALL Medizin** evaluating depot subcutaneous immunotherapy, along with randomized placebo-controlled studies and publication reports supporting clinical efficacy and tolerability in Parietaria-associated rhinoconjunctivitis with or without mild asthma.

Other names

Parietaria judaica pollen extractParietaria pollen vaccineParietaria judaica extractP. judaica pollen extract